ArticleCancers2020

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers.

Sarah Jannier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.